INCA-6 Triptycene-1,4-quinone|cas:3519-82-2|西域试剂

INCA-6 Triptycene-1,4-quinone,98.85%

产品编号：Bellancom-108544| CAS NO：3519-82-2| 分子式：C₂₀H₁₂O₂| 分子量：284.31

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-108544	￥1700.00	杭州北京（现货）
Bellancom-108544	￥2700.00	杭州北京（现货）
Bellancom-108544	￥5400.00	杭州北京（现货）
Bellancom-108544	￥8640.00	杭州北京（现货）
Bellancom-108544	￥13800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

INCA-6 Triptycene-1,4-quinone

产品介绍

INCA-6 (Triptycene-1,4-quinone) 是一种细胞渗透性 NFAT 抑制剂。INCA-6 特异性阻断 NFAT底物靶向钙调神经磷酸酶位点，是 calcineurin (CN)-NFAT 信号传导的有效抑制剂。

生物活性

INCA-6 (Triptycene-1,4-quinone) is a cell-permeable NFAT inhibitor. INCA-6 specifically blocks targeting of NFAT(P) substrate to the calcineurin (CN) phosphatase site and is an effective inhibitor of CN-NFAT signaling.

体外研究

INCA-6 (5 μM; for 24-hour) prevents transient outward K+ current (Ito) downregulation in 3-Hz cells.
Pre-treatment of BV-2 cells with INCA-6 (10 μM) significantly inhibits ATP-induced CXCL2 expression in BV-2 cells. INCA-6 also inhibits ATP-induced CXCL2 expression in rat primary microglia.
INCA-6 (5 μM) reduces SERCA2 transcript levels as well as protein expression, in the absence or in the presence of thapsigargin (TG).
INCA-6 (1.0 and 2.5 μM; 24 hours ) treatment significantly decreases both VEGF and serum-induced human retinal microvascular endothelial cells (HRMEC) proliferation, but does not affect baseline proliferation^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[4]

Cell Line:	Human retinal microvascular endothelial cells
Concentration:	0.5, 1.0, or 2.5 μM
Incubation Time:	24 hours
Result:	Significantly inhibited VEGF-induced proliferation at 1.0 and 2.5 μM concentrations.

体内研究
(In Vivo)

INCA-6 (5.0, or 25.0 μM) treatment significantly reduces pathologic neovascularization in oxygen-induced retinopathy (OIR)^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rats bearing OIR model^[4]
Dosage:	2.5, 5.0, or 25.0 μM
Administration:	Intravitreal injection on days 14(0) and 14(3)
Result:	Decreased the severity of OIR in a dose dependent manner. Significant inhibition was seen at 5.0 and 25.0 μM concentrations.

体内研究

INCA-6 (5.0, or 25.0 μM) treatment significantly reduces pathologic neovascularization in oxygen-induced retinopathy (OIR)^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rats bearing OIR model^[4]
Dosage:	2.5, 5.0, or 25.0 μM
Administration:	Intravitreal injection on days 14(0) and 14(3)
Result:	Decreased the severity of OIR in a dose dependent manner. Significant inhibition was seen at 5.0 and 25.0 μM concentrations.

体内研究

INCA-6 (5.0, or 25.0 μM) treatment significantly reduces pathologic neovascularization in oxygen-induced retinopathy (OIR)^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rats bearing OIR model^[4]
Dosage:	2.5, 5.0, or 25.0 μM
Administration:	Intravitreal injection on days 14(0) and 14(3)
Result:	Decreased the severity of OIR in a dose dependent manner. Significant inhibition was seen at 5.0 and 25.0 μM concentrations.